埃蒂福克辛与阿尔普拉佐拉姆在带有体征症状的泛性焦虑症中的有效性和安全性:一项随机,双盲,比较性研究
Kalmegh Prabhakar1, Gopalakrishnan Ganesan2, Dhananjay Chaudhari3
1Department of Psychiatry, Medipoint Hospital Pvt. Ltd, Maharashtra, India.
Journal of anxiety disorders
|February 28, 2026
概括
埃蒂福克辛有效地管理了带有体征症状的泛性焦虑障碍 (GAD),显示出对阿尔普拉佐兰的非劣势性. 这种耐受良好的抗焦虑药物为焦虑治疗提供了一个有希望的替代方案,没有依赖的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
- 临床试验 临床试验
背景情况:
- 泛性焦虑症 (GAD) 经常表现出显著的身体症状.
- 非二胺抗焦虑药,如Etifoxine,在治疗GAD体征症状方面的疗效需要进一步研究.
- 将Etifoxine与Alprazolam等已知治疗方法进行比较对于了解其治疗潜力至关重要.
研究的目的:
- 为了比较Etifoxine与Alprazolam在被诊断患有GAD和体征症状的成年人中的疗效和安全性.
- 评估Etifoxine在减少整体焦虑症状严重程度方面与阿尔普拉佐拉姆的非劣势.
- 评估Etifoxine对GAD患者精神和体质症状子评分的影响.
主要方法:
- 第三阶段,随机,双盲,双模拟研究,涉及260名患有GAD和体征症状的成年患者.
- 患者接受了Etifoxine 50 mg三次一天或Alprazolam 0.5 mg三次一天,持续4周.
- 主要结局:汉密尔顿焦虑评分表 (HAM-A) 总得分从基线到28日的变化. 其次要结果包括HAM-A子分数和全球印象尺度.
主要成果:
- 埃提福辛和阿尔普拉佐拉姆在28天的HAM-A总得分都显示出了统计学上显著的降低 (p < 0.0001).
- 埃提福克辛被发现与阿尔普拉佐拉姆无差,在初级和二级结局措施中具有可比的疗效.
- 治疗出现的不良事件是轻微的,在两组中报告的比例相似 (10%的埃蒂福辛与7.7%的阿尔普拉佐拉姆).
结论:
- 埃蒂福克辛在管理GAD成年人的焦虑症状方面与阿尔普拉佐兰无差,包括体质投诉.
- 埃蒂福克辛耐受性良好,并且由于其非二胺的特征和较低的依赖风险,它是一个潜在的更安全的替代品.
- 这些发现支持埃蒂福克辛作为一种可行的治疗选择,用于治疗患有体征症状的GAD患者的焦虑症.
更多相关视频
相关概念视频
01:29Anxiolytic Drugs: Benzodiazepines and Buspirone
2.8K
Benzodiazepines are a class of anxiolytic drugs known for their rapid efficacy and high therapeutic-to-lethal dose ratio, but with a potential risk of drug dependence. These drugs are lipophilic, allowing for rapid absorption after oral administration, eventually reaching the central nervous system (CNS). Once in the CNS, benzodiazepines bind to the allosteric site of the GABAA receptor. This binding enhances the inhibitory effects of the neurotransmitter GABA. By doing so, they prevent...
2.8K
01:26Anxiolytic Drugs: Overview
1.3K
Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic...
1.3K
01:30Generalized Anxiety Disorder
870
Generalized Anxiety Disorder (GAD) is a chronic condition characterized by excessive and uncontrollable worry that persists for at least six months, significantly interfering with daily functioning. Unlike situational anxiety, which arises in response to specific stressors, GAD often occurs without a clear cause. Individuals may experience disproportionate worry about work, health, or relationships. For instance, a person might continuously fear poor health despite normal medical evaluations or...
870
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
708
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
708
01:20Antiepileptic Drugs: Potassium Channel Activators
867
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
867
01:54The Placebo Effect
6.9K
The placebo effect occurs when people's expectations or beliefs influence or determine their experience in a given situation. In other words, simply expecting something to happen can actually make it happen.
6.9K